Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Deckers Outdoor Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Deckers Outdoor Corp trades at $94.19 (market cap $13.27B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Deckers Outdoor Corp's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DECK | |
|---|---|---|
Market Cap | $29.03B | $13.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $123.91 |
52-Week Low | $205.48 | $79.54 |
Enterprise Value | $26.99B | $12.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.
Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.
Deckers Outdoor (DECK) trades at $97.46, down 0.42% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $0.96 beating expectations of $0.81. Revenue grew to $4.99 billion in 2025 with impressive 18.36% net margin and 42.56% ROE. Analyst consensus remains positive with 45% buy ratings and $122.40 price target, though recent guidance concerns caused a 6% selloff.
DECK offers compelling value with a 13.86 P/E ratio below industry averages, supported by HOKA and UGG brand strength. Key risks include tariff headwinds, brand concentration, and execution challenges. The stock presents a growth opportunity at current levels but faces near-term volatility from macroeconomic pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
